Form 4: Coherus Director Michael Lee Ryan Receives Equity Grant

Director Michael Lee Ryan was granted 30,000 restricted stock units and 60,000 stock options by Coherus Oncology, Inc.

Summary

• Director Michael Lee Ryan acquired 30,000 restricted stock units (RSUs) on June 5, 2026.
• Director Michael Lee Ryan was granted 60,000 stock options with an exercise price of $1.45 per share.
• The RSUs vest 100% on the one-year anniversary of June 3, 2026.
• The stock options vest and become exercisable 100% on June 3, 2027.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which is neutral for the stock price.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• Potential for future shareholder dilution upon the vesting and exercise of these equity awards.

Risks

• Vesting of these awards is contingent upon the director's continued service relationship with the company.

Future Outlook

The equity grants are subject to continued service requirements, indicating a retention-focused compensation strategy for the director.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard corporate governance practice in the biotechnology sector to ensure board members are incentivized to oversee long-term strategic growth.

Comparison to Industry Standards

• The use of time-based vesting for director equity is consistent with standard practices among mid-cap biotechnology firms.
• The grant size is typical for non-executive director compensation packages in the sector.

Stakeholder Impact

• Shareholders may experience minor dilution upon the eventual exercise of these options.

Next Steps

• Vesting of RSUs on June 3, 2027.
• Vesting of stock options on June 3, 2027.

Key Dates

Keywords

Coherus Oncology, CHRS, Form 4, Insider Trading, Equity Compensation, Director Compensation